Myqorzo and Redemplo approved in China Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndromeUnderscores Sanofi's long-term commitment to ...

In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.

For the first time this century, a drop in deceased donors reduced total kidney transplants in 2025, a paradox that occurred ...

After now winning seven games in the final two minutes of the fourth quarter, the Chicago Bears have adopted a new name, the ...

Indian Idol winner Prashant Tamang’s sudden death at 43 has renewed focus on how hidden heart conditions, sleep-related ...

Medical professionals aren’t sure what causes the ‘spontaneous’ condition which is often diagnosed only after an event like a ...

Heart attacks in youngsters are rising globally. Firstpost got in touch with Dr. Zeeshan Mansuri, who explained the key ...

Work in our modern world has been replaced from physical movement to sedentary behaviour. And after 40, sitting for long ...

Medical emergencies often seem sudden, but in many cases, our bodies give warning signs that can be detected in advance ...

Heart attacks aren't random. Discover the 4 key controllable risk factors: high BP, cholesterol, sugar & smoking. Take ...

These are the symptoms to look out for and steps to take if you think you're having a heart attack. With a heart attack, ...

Many heart patients recall subtle symptoms weeks before a major event. Jaw pain, unexplained fatigue, or breathlessness are ...